Tolerance-induction Phototherapy Effective and Safe for Solar Urticaria, suggests study

Written By :  Dr. Shravani Dali
Published On 2026-03-30 14:45 GMT   |   Update On 2026-03-30 14:46 GMT

According to a new study, Tolerance-induction phototherapy with UVA or NB-UVB is a safe and highly effective first-line treatment for solar urticaria. It offers durable phototolerance and long-term remission and extended follow-up confirms its sustained efficacy and favorable safety in real-world practice.

Solar urticaria (SU) is a rare, chronic photodermatosis characterized by immediate whealing upon exposure to ultraviolet (UV) or visible light. Tolerance-induction phototherapy (photohardening), delivered as action-spectrum desensitization or cross-spectrum photohardening, represents the mainstay of management in antihistamine-refractory cases, yet data on its long-term real-world efficacy and safety remain limited. The aim of the study was to evaluate the clinical and photobiological characteristics, therapeutic outcomes, and long-term efficacy of tolerance-induction phototherapy in patients with SU managed at a tertiary phototherapy center. A retrospective observational study was conducted on 53 patients with phototest-confirmed SU treated with UVA or narrowband UVB (NB-UVB) phototherapy between January 2005 and June 2025. Treatment regimens were tailored to individual action spectra and, in selected cases, applied as cross-spectrum photohardening according to clinical practice and safety considerations. Clinical responses, phototolerance (minimal urticarial dose, MUD), and adverse events were recorded. Long-term outcomes, including remission persistence, relapse, and patient satisfaction, were assessed through complete follow-up (median 4.7 years).

At the end of therapy, 33 patients (62%) achieved complete remission, 15 (28%) partial improvement, and 5 (9%) showed no change; overall, 91% experienced at least partial benefit. Remission was maintained in 31 patients (58%), while 22 (42%) relapsed after a mean of 4.2±1.6 years. In patients with available post-treatment phototesting, those maintaining remission exhibited a mean fourfold increase in phototolerance. The mean satisfaction score was 8.8±0.7 (median 9). Only mild transient erythema (15%) and pruritus (7%) were reported, with no serious adverse events.

Tolerance-induction phototherapy with UVA or NB-UVB is a safe and highly effective first-line treatment for solar urticaria, providing durable phototolerance and long-term remission in most patients. The extended follow-up confirms its sustained efficacy and favorable safety profile in real-world clinical practice.

Reference:

Bighetti S, Bettolini L, Venturini M, Calzavara-Pinton P, Galli B, Cattaneo I, et al. Real-life experience from a tertiary phototherapy center on solar urticaria: clinical features, management, and long-term outcomes from a twenty-year cohort. Ital J Dermatol Venereol 2026 Mar 23. DOI: 10.23736/S2784-8671.26.08542-7


Keywords:

Tolerance-induction, Phototherapy, Effective, Safe, Solar, Urticaria, solar; Phototherapy; Dermatology, Bighetti S, Bettolini L, Venturini M, Calzavara-Pinton P, Galli B, Cattaneo I,




Tags:    
Article Source : Italian Journal of Dermatology and Venereology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News